The Immune Guard Study
The study drug is exploring a potential new treatment for disorders of a crucial part of the immune system.
Complement-mediated diseases, such as IgA Nephropathy (IgAN), Paroxysmal Nocturnal Haemoglobinuria (PNH), and Atypical Haemolytic Uraemic Syndrome (aHUS), affect the kidneys and blood. Current treatments often require frequent doses and can have significant side effects. This study is evaluating a potential new treatment that aims to targets a protein involved in these diseases. This potential new treatment aims to provide a long-lasting option with fewer side effects by being administered as a single injection under the skin.
This study is a crucial step before testing the new treatment in patients. By participating, you will contribute to research that could lead to more convenient and effective treatments for complement-mediated diseases. Your involvement will help researchers determine the best way to administer this potential therapy, ensuring it is both practical and widely available.
Call us on 1300 854 231 to discuss your eligibility today!